| Literature DB >> 33139851 |
Shoutaro Arakawa1,2, Ryusuke Suzuki3,4, Daisaburo Kurosaka3, Ryo Ikeda3, Hiroteru Hayashi3, Tomohiro Kayama3, Rei-Ichi Ohno4, Ryoji Nagai4, Keishi Marumo3, Mitsuru Saito3.
Abstract
Advanced glycation end-products (AGEs) deteriorate bone strength. Among over 40 species identified in vivo, AGEs other than pentosidine were roughly estimated as total fluorescent AGEs (tfAGEs) due to technical difficulties. Using LC-QqTOF-MS, we established a system that enabled the quantitation of five AGEs (CML, CEL, MG-H1, CMA and pentosidine) as well as two mature and three immature enzymatic crosslinks. Human bone samples were collected from 149 patients who underwent total knee arthroplasty. Their clinical parameters were collected to investigate parameters that may be predictive of AGE accumulation. All the analytes were quantitated and showed significant linearity with high sensitivity and precision. The results showed that MG-H1 was the most abundant AGE, whereas pentosidine was 1/200-1/20-fold less abundant than the other four AGEs. The AGEs were significantly and strongly correlated with pentosidine, while showing moderate correlation with tfAGEs. Interestingly, multiple linear regression analysis revealed that gender contributed most to the accumulation of all the AGEs, followed by age, tartrate-resistant acid phosphatase-5b and HbA1c. Furthermore, the AGEs were negatively correlated with immature crosslinks. Mass spectrometric quantitation of AGEs and enzymatic crosslinks is crucial to a better understanding of ageing- and disease-related deterioration of bone strength.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33139851 PMCID: PMC7606603 DOI: 10.1038/s41598-020-75923-8
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1The pathways of AGEs formation.
Figure 2AGEs analyzed in this study. (a) CML, N-(carboxymethyl)lysine; (b) CEL, N-(carboxyethyl)lysine; (c) MG-H1, N-(5-hydro-5-methyl-4-imidazolon-2-yl)-ornithine 1; (d) CMA, N-(carboxymethyl)arginine; (e) pentosidine.
Clinical characteristics of the participants.
| Total | Male | Female | ||
|---|---|---|---|---|
| (n = 149) | (n = 31) | (n = 118) | ||
| Age (years) | 73.95 ± 8.08 | 74.35 ± 8.31 | 73.85 ± 8.05 | 0.762 |
| BMI (kg/m2) | 25.72 ± 3.61 | 25.34 ± 2.54 | 25.81 ± 3.84 | 0.435 |
| Hypertension (n, %) | 78, 52.35 | 13, 41.94 | 65, 55.08 | n/a |
| Dyslipidemia (n, %) | 41, 27.52 | 4, 12.90 | 37, 31.36 | n/a |
| eGFR (mL/min/1.73 m2) | 64.70 ± 13.01 | 66.13 ± 11.33 | 64.33 ± 13.44 | 0.454 |
| HbA1c (%) | 5.86 ± 0.41 | 5.76 ± 0.43 | 5.88 ± 0.40 | 0.158 |
| TRACP-5b (mU/dL) | 272.0 ± 127.2 | 267.3 ± 107.3 | 273.2 ± 132.3 | 0.797 |
Values are shown as the mean ± standard deviation, or as labeled.
BMI Body Mass Index, eGFR estimated glomerular filtration rate, TRACP-5b tartrate-resistant acid phosphatase-5b.
Figure 3Typical extracted ion chromatographic peaks of AGEs and enzymatic crosslinks (theoretical m/z ± 0.005). (a) CML, N-(carboxymethyl)lysine; (b) CEL, N-(carboxyethyl)lysine; (c) MG-H1, N-(5-hydro-5-methyl-4-imidazolon-2-yl)-ornithine 1; (d) CMA, N-(carboxymethyl)arginine; (e) pentosidine; (f) DHLNL, dihydroxylysinonorleucine; (g) HLNL, hydroxylysinonorleucine; (h) LNL, lysinonorleucine; (i) PYD, pyridinoline; (j) DPD, deoxypyridinoline.
Linearity, sensitivity, precision and recovery of the analytes.
| Matrix | Analyte | Linearity | Sensitivity (nM) | Precision (%) | Recovery (%) | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Spiked range (nM) | r2 | LOD | LOQ | Intraday | Interday | 10 (pmol) | 20 (pmol) | 40 (pmol) | ||
| 0.1% formic acid | ||||||||||
| Hyp | 0–250,000.00 | 1.000 | 32.43 | 98.27 | 0.50 | 0.63 | – | – | – | |
| AGEs | ||||||||||
| CML | 0–1000.00 | 0.998 | 7.74 | 23.45 | 1.72 | 2.19 | – | – | – | |
| CEL | 0–1000.00 | 1.000 | 13.85 | 41.98 | 1.38 | 1.83 | – | – | – | |
| MG-H1 | 0–1000.00 | 1.000 | 6.01 | 18.22 | 1.37 | 1.91 | – | – | – | |
| CMA | 0–1000.00 | 1.000 | 7.69 | 23.30 | 1.95 | 2.42 | – | – | – | |
| Pentosidine | 0–500.00 | 1.000 | 7.95 | 24.09 | 3.18 | 3.22 | – | – | – | |
| DHLNL | 0–1000.00 | 1.000 | 5.26 | 15.95 | 1.65 | 2.53 | – | – | – | |
| HLNL | 0–1000.00 | 1.000 | 6.52 | 19.75 | 2.65 | 2.44 | – | – | – | |
| LNL | 0–1000.00 | 1.000 | 5.61 | 16.99 | 2.06 | 2.02 | – | – | – | |
| PYD | 0–1000.00 | 1.000 | 11.34 | 34.36 | 4.55 | 6.47 | – | – | – | |
| DPD | 0–1000.00 | 1.000 | 11.46 | 34.73 | 3.57 | 6.26 | – | – | – | |
| Bone hydrolysate | ||||||||||
| Hyp | 0–250,000.00 | – | 10,908.52 | 33,056.12 | 2.09 | 4.53 | 8.55 ± 0.11 | 8.93 ± 0.03 | 9.39 ± 0.04 | |
| CML | 0–250 | 0.997 | 21.20 | 64.23 | 3.37 | 3.46 | 84.64 ± 2.04 | 70.71 ± 0.41 | 71.35 ± 1.59 | |
| CEL | 0–250 | 0.999 | 13.57 | 41.12 | 4.72 | 3.90 | 92.11 ± 1.60 | 86.92 ± 0.93 | 85.93 ± 0.20 | |
| MG-H1 | 0–1000 | 0.998 | 71.05 | 215.29 | 3.85 | 3.29 | 72.26 ± 0.80 | 64.84 ± 0.04 | 70.42 ± 0.46 | |
| CMA | 0–250 | 1.000 | 7.61 | 23.05 | 5.03 | 4.62 | 66.98 ± 1.05 | 68.13 ± 0.38 | 65.49 ± 0.98 | |
| Pentosidine | 0–250 | 0.999 | 10.14 | 30.72 | 3.62 | 4.94 | 100.48 ± 7.36 | 94.30 ± 2.53 | 98.08 ± 2.94 | |
| DHLNL | 0–250 | 1.000 | 9.37 | 28.39 | 2.03 | 12.39 | 58.45 ± 6.74 | 58.70 ± 3.59 | 52.89 ± 2.01 | |
| HLNL | 0–250 | 1.000 | 10.42 | 31.58 | 4.53 | 6.11 | 55.02 ± 9.15 | 54.76 ± 2.70 | 51.90 ± 2.37 | |
| LNL | 0–250 | 1.000 | 4.69 | 14.20 | 2.07 | 8.14 | 50.39 ± 1.14 | 52.57 ± 0.99 | 51.14 ± 1.01 | |
| PYD | 0–250 | 0.999 | 15.65 | 47.41 | 5.43 | 6.35 | 74.89 ± 5.51 | 64.07 ± 2.03 | 66.54 ± 2.62 | |
| DPD | 0–250 | 1.000 | 10.07 | 30.51 | 3.53 | 7.08 | 47.31 ± 3.31 | 53.84 ± 1.52 | 52.53 ± 0.64 | |
LOD limit of detection, LOQ limit of quantitation, Hyp hydroxyproline, CML N-(carboxymethyl)lysine, CEL N-(carboxyethyl)lysine, MG-H1 N-(5-hydro-5-methyl-4-imidazolon-2-yl)-ornithine 1, CMA N-(carboxymethyl)arginine, DHLNL dihydroxylysinonorleucine, HLNL hydroxylysinonorleucine, LNL lysinonorleucine, PYD pyridinoline, DPD deoxypyridinoline.
Figure 4AGEs and enzymatic crosslinks in human cancellous bone from lateral tibia plateau. The filled bar and error bar reflect mean value and standard deviation. Abbreviations: Hyp, hydroxyproline; CML, N-(carboxymethyl)lysine; CEL, N-(carboxyethyl)lysine; MG-H1, N-(5-hydro-5-methyl-4-imidazolon-2-yl)-ornithine 1; CMA, N-(carboxymethyl)arginine; DHLNL, dihydroxylysinonorleucine; HLNL, hydroxylysinonorleucine; LNL, lysinonorleucine; PYD, pyridinoline; DPD, deoxypyridinoline.
Correlation analyses between the AGEs and tfAGEs.
| CEL | MG-H1 | CMA | Pentosidine | tfAGEs | |
|---|---|---|---|---|---|
| rs | rs | rs | rs | rs | |
| CML | 0.960*** | 0.933*** | 0.639*** | 0.920*** | 0.400*** |
| CEL | – | 0.922*** | 0.682*** | 0.886*** | 0.342*** |
| MG-H1 | – | – | 0.639*** | 0.910*** | 0.332*** |
| CMA | – | – | – | 0.614*** | 0.002 |
| Pentosidine | – | – | – | – | 0.313*** |
CML N-(carboxymethyl)lysine, CEL N-(carboxyethyl)lysine, MG-H1 N-(5-hydro-5-methyl-4-imidazolon-2-yl)-ornithine 1, CMA N-(carboxymethyl)arginine, tfAGEs total fluorescent AGEs; r Spearman’s coefficient.
*p < 0.05; **p < 0.01; ***p < 0.001.
Multiple stepwise linear regression analysis using each AGE content as the dependent variable, while gender, age, TRACP-5b, HbA1c, BMI and eGFR as the independent variables.
| CML | CEL | MG-H1 | CMA | Pentosidine | |
|---|---|---|---|---|---|
| ß | ß | ß | ß | ß | |
| Gender (female) | − 0.424*** | − 0.414*** | − 0.380*** | − 0.232** | − 0.351*** |
| Age | 0.231** | 0.251*** | 0.292*** | 0.194* | 0.302*** |
| TRACP-5b | − 0.285*** | − 0.244*** | − 0.254*** | − 0.258*** | − 0.278*** |
| HbA1c | 0.187** | 0.212** | 0.175* | 0.179* | 0.091 |
| BMI | 0.166* | 0.095 | 0.158* | – | 0.133 |
| Adjusted R2 | 0.347 | 0.318 | 0.316 | 0.160 | 0.282 |
CML N-(carboxymethyl)lysine, CEL N-(carboxyethyl)lysine, MG-H1 N-(5-hydro-5-methyl-4-imidazolon-2-yl)-ornithine 1, CMA N-(carboxymethyl)arginine, TRACP-5b, tartrate-resistant acid phosphatase-5b, ß standardized regression coefficient, BMI Body Mass Index.
*p < 0.05; **p < 0.01; ***p < 0.001.
Correlation analyses of the lys-derived AGEs (i.e. CML, CEL and pentosidine) and the enzymatic crosslinks.
| CML | CEL | Pentosidine | |
|---|---|---|---|
| rs | rs | rs | |
| DHLNL | − 0.417*** | − 0.471*** | − 0.422*** |
| HLNL | − 0.676*** | − 0.695*** | − 0.656*** |
| LNL | − 0.285*** | − 0.350*** | − 0.300*** |
| PYD | 0.010 | − 0.004 | − 0.011 |
| DPD | 0.026 | − 0.037 | 0.000 |
CML N-(carboxymethyl)lysine, CEL N-(carboxyethyl)lysine, DHLNL dihydroxylysinonorleucine, HLNL hydroxylysinonorleucine, LNL lysinonorleucine, PYD pyridinoline, DPD deoxypyridinoline, r Spearman’s coefficient.
*p < 0.05; **p < 0.01; ***p < 0.001.